4th China BioPharma Week-Antibody & Vaccine Focus 2014 is the region’s leading event dedicated to scientific, technology and business development: a strategic keynote conference, real life case studies and interactive roundtables.
Why You Should Attend in 2014?
Authoritative Interpreting of Global BioPharma Development Market Trends
Forefront of Innovation and New Technology Breakthrough in BioPharma Industry
Further Study of the Market Strategy and Technology Application
Study to Optimize Antibody & Vaccine Design, Engineering and Production
Exploring the Project Cooperation and Investment Opportunity in Asia Especially in China
Unique Opportunity of One-on-One Meetings
Don't Just Take Our Word for It:
This is a high quality international conference with excellent group of speakers & participants. Very well organized, provided enough opportunity for people to interact. Looking forward to the future events. GUO Yajun, Director, Chinese National Engineering Research Centre for Antibody Medicine
Excellent conference with great mix of speakers. It provided good platform to learn for scientists who are antibody experts and new in the field. Plenty opportunities to interact with old friends and to meet new ones. ZHU Zhenping, EVP, Kadmon Pharmaceuticals
This is a very exciting events, with participants from both academia and pharma industry. There is something new for both new-comers to the therapeutics Ab fields and veterans in the industry as well. Great networking opportunities! Dr. John L. Xu, Associate Director, Biologics, GSK R&D China
Very professionally organized, good questions and knowledgeable topics. Dr. Klaus WILGENBUS, Corporate Senior Vice President, Boehringer Ingelheim
4th China BioPharma Convention-Antibody & Vaccine Focus 2014
Biotech drugs have entered the large-scale production stage worldwide. Following the pace, the State Council policy documents have listed the biopharmaceutical as a key development area. It’s expected in 2015 that the volume of China's biopharmaceutical market is expected to reach $100 billion, and antibody drug industry output value will exceed 40 billion. Meanwhile, by the end of 2013, China’s vaccine total production is more than 20 billion RMB, and has steadily grown at an average annual rate of 18%. As the strategic products which are critical to the revitalization of national development, vaccine industry development has been paid much emphasis and stimulated by government powerful policies. More...
Biotech drugs have entered the large-scale production stage worldwide. Following the pace, the State Council policy documents have listed the biopharmaceutical as a key development area. It’s expected in 2015 that the volume of China's biopharmaceutical market is expected to reach $100 billion, and antibody drug industry output value will exceed 40 billion. Meanwhile, by the end of 2013, China’s vaccine total production is more than 20 billion RMB, and has steadily grown at an average annual rate of 18%. As the strategic products which are critical to the revitalization of national development, vaccine industry development has been paid much emphasis and stimulated by government powerful policies.
